Myungmoon Mobinul Injection 1 Milliliter (Glycopyrrolate)

Adult administration

During anesthesia Preoperative administration: 30-60 minutes before the anticipated induction of anesthesia, or as preanesthetic medication (narcotic and/or sedative), administer the recommended dose of glycopyrrolate 0.004 mg (0.02 mL) per kg of body weight by intramuscular injection. Intraoperative administration: Administer to prevent vagal reflexes induced by drugs or associated with arrhythmias. Give 0.1 mg (0.5 mL) intravenously per dose; repeat at 2-3-minute intervals if necessary. Determine the number of doses after identifying the cause of the arrhythmia, and take appropriate measures during surgery and anesthesia to correct parasympathetic imbalance. Administration for reversal of neuromuscular blockade: Administer glycopyrrolate 0.2 mg (1 mL) intravenously for every 1.0 mg of neostigmine or 5.0 mg of pyridostigmine. To minimize cardiac effects, the drugs may be administered simultaneously by intravenous injection and mixed together. Adjunctive treatment of peptic ulcer Administer 0.1 mg (0.5 mL) of glycopyrrolate per dose by subcutaneous, intramuscular, or intravenous injection 3-4 times daily at 4-hour intervals. A dose of 0.2 mg (1.0 mL) may be administered if a stronger effect is required.

Child administration

Preoperative administration: In children aged 1 month-12 years, administer the recommended dose of glycopyrrolate 0.004 mg (0.02 mL) per kg of body weight by intramuscular injection 30-60 minutes before the anticipated induction of anesthesia, or as preanesthetic medication (narcotic and/or sedative). Preoperative administration: In children aged 1 month-2 years, 0.008 mg (0.04 mL) per kg of body weight may be administered. Intraoperative administration: Administer 0.004 mg (0.02 mL) per kg of body weight intravenously; do not exceed 0.1 mg (0.5 mL) per dose. If repeated, administer at 2-3-minute intervals. Administration for reversal of neuromuscular blockade: Administer glycopyrrolate 0.2 mg (1 mL) intravenously for every 1.0 mg of neostigmine or 5.0 mg of pyridostigmine. To minimize cardiac effects, the drugs may be administered simultaneously by intravenous injection and mixed together.

This medication can cause severe respiratory issues in premature infants due to the benzyl alcohol component. Care must be taken when handling the injection container as glass shards may enter. It should be handled especially carefully when used on children or the elderly. It must not be used by individuals with allergies to this drug, neonates, or premature infants. It is also not recommended for individuals with glaucoma, specific urinary tract conditions, gastrointestinal obstruction, cardiovascular issues, severe colitis, or myasthenia gravis. Special precautions are needed for pregnant or breastfeeding women and patients with heart conditions, asthma, or thyroid dysfunction. This medication can cause side effects such as dry mouth, urinary difficulties, urinary retention, blurred vision due to dilation, increased intraocular pressure, tachycardia, palpitations, decreased sweating, loss of taste, headache, nervousness, drowsiness, weakness, dizziness, insomnia, nausea, vomiting, impotence, suppression of lactation, a feeling of swelling, particular sensitivities, and confusion or agitation in the elderly. Use in high-temperature environments can reduce sweating and increase the risk of heat stroke. Drowsiness or visual disturbances may occur, so driving or operating dangerous machinery should be avoided. In case of overdose, professional treatment is necessary, and in severe cases, artificial respiration may be required. Care must be taken when mixing this drug with other medications, as it should not be mixed with some drugs, and caution is needed during mixing. When administering this drug intravenously during anesthesia, it must be done very slowly due to the risk of cardiac arrhythmias.

• Dry mouth
• urinary disturbances
• urinary retention
• blurred vision due to mydriasis
• increased intraocular pressure
• tachycardia
• palpitations
• decreased sweating
• loss of taste
• headache

This medication should be stored in a sealed container to prevent exposure to air and kept at a temperature between 1 and 30 degrees Celsius. Storing this way helps maintain the medication’s efficacy and prevents degradation.

Appearance

A colorless, transparent liquid contained in a colorless, transparent ampule.

Package unit

1 ampule (1mL) × 50, 1 ampule (1mL) × 10 (for export)